Neoadjuvant immunotherapy does not increase postoperative complications.

A comprehensive analysis of 953,612 cancer surgery patients reveals neoadjuvant immunotherapy is not significantly linked to major postoperative morbidity. The study, which evaluated cases across multiple cancer types, found a pooled odds ratio of 0.98, indicating no increased risk. Specifically, adjusted odds ratios varied by cancer type, with none showing significant associations with complications. The findings suggest that surgical procedures following neoadjuvant immunotherapy are generally safe, providing reassurance for ongoing treatment protocols.